The World’s Most Clinically Advanced and Scientifically Validated Molecular DNA Biomarker Test for Oral Squamous Cell Carcinoma is Launching in Late Spring
HAVERTOWN, PA–(Marketwired – Apr 3, 2014) – PeriRx LLC, a premier developer of breakthrough, non-invasive, oral diagnostic technology recently announced that it will be introducing the world’s most clinically advanced and scientifically validated molecular DNA biomarker test for oral squamous cell carcinoma detection in the late spring. [Read more…]
Improving early detection of oral squamous cell carcinoma with advanced salivary diagnostics may impact mortality
Oral cancer is the sixth most prevalent form of cancer in the United States. According to the Oral Cancer Foundation and the National Cancer Institute, approximately 43,000 people in the U.S. will be newly diagnosed with oral cancer in 2014. This includes those cancers that occur in the mouth itself, in the very back of the mouth, known as the oropharynx, and on the exterior lip of the mouth.
Oral cancer is also curable if detected early enough. [Read more…]
According to the National Cancer Institute, an estimated 40,250 people were diagnosed with cancer of the oral cavity and pharynx in the United States in 2012. The five-year survival rate for those diagnosed with early-stage oral and pharyngeal cancers is 82.4 percent. The five-year survival rate of those diagnosed with late-stage metastasized oral and pharyngeal cancers is 34.9 percent. [Read more…]
November 28, 2012 — A Pennsylvania start-up is gearing up to launch a molecular saliva test that analyzes biomarkers to detect oral cancer and diabetes. PeriRx is now conducting clinical trials of its diagnostic test, which has attracted the interest of the U.K.’s National Institute for Health Research.
The genesis for the test came from a collaboration between Neil Gottehrer, DDS, a Havertown, PA, dentist who has been practicing for 38 years, and David T.W. Wong, DMD, DMSc, a pioneer in salivary diagnostics who is the associate dean of research and a professor of oral biology at the University of California, Los Angeles (UCLA) School of Dentistry. [Read more…]
In 2008, Pennsylvania doctors, Neil Gottehrer, DDS, and David T.W. Wong, DMD, DMSc, began collaborating on a project to develop a cutting-edge test that would analyze molecular biomarkers in saliva to detect oral cancer. Using Gottehrer’s 38 years of experience as a dentist and Wong’s pioneering research in salivary diagnostics, the two have successfully changed the way doctors, dentists and hygienists screen for oral cancer. [Read more…]
HAVERTOWN — A personalized medicine company is out to make a trip to the dentist more meaningful than simply a checkup for cavities and a teeth cleaning.
PeriRx has licensed and is completing the development of a non-invasive saliva test for dentists that can be used to detect and predict oral cancer — the world’s sixth most common cancer.
Stephen M. Swanick, CEO of PeriRx, said the 4-year-old Delaware County company is in discussions with several large pharmaceutical companies, including GlaxoSm-thKline and Johnson & Johnson, about teaming up on the distribution of its molecular diagnostic test for oral cancer and a second product targeted the early diagnosis of diabetes. [Read more…]
In this week’s print edition, I have a story about PeriRx, a Havertown, Pa., personalized medicine company that is getting ready to launch a diagnostic test dentists can use to detect oral cancer by collecting saliva samples to be analyzed for certain biomarkers. [Read more…]
A Michigan State University surgeon is teaming up with a Lansing-area dental benefits firm on a clinical trial to create a simple, cost-effective saliva test to detect oral cancer, a breakthrough that would drastically improve screening and result in fewer people dying of the world’s sixth most common cancer. [Read more…]
Prevalidation of Salivary Biomarkers for Oral Cancer Detection
David Elashoff, Hui Zhou, Jean Reiss, et al.
Cancer Epidemiol Biomarkers Prev 2012;21:664-672. Published OnlineFirst February 1, 2012.
It appears to, according to a study in Community Dentistry and Oral Epidemiology (August 24, 2011). White patients are twice as likely to be recommended for surgery for oral and oropharyngeal cancer as black patients, according to researchers from the Medical University of South Carolina. The researchers weren’t surprised to find racial discrimination in cancer treatment, but they didn’t expect it to be so prevalent, they said. [Read more…]